Johnson & Johnson (JNJ) Surpasses Market Returns: Some Facts Worth Knowing

In the latest close session, Johnson & Johnson (JNJ) was up +1.98% at $239.93. The stock exceeded the S&P 500, which registered a gain of 0.54% for the day. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated Nasdaq saw an increase of 0.77%.

The world's biggest maker of health care products's stock has dropped by 4.47% in the past month, exceeding the Medical sector's loss of 8.43% and the S&P 500's loss of 4.71%.

Analysts and investors alike will be keeping a close eye on the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report is set to go public on April 14, 2026. The company's upcoming EPS is projected at $2.69, signifying a 2.89% drop compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $23.44 billion, showing a 7.06% escalation compared to the year-ago quarter.

For the full year, the Zacks Consensus Estimates project earnings of $11.54 per share and a revenue of $100.36 billion, demonstrating changes of +6.95% and +6.55%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for Johnson & Johnson. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.04% higher. Right now, Johnson & Johnson possesses a Zacks Rank of #2 (Buy).

Investors should also note Johnson & Johnson's current valuation metrics, including its Forward P/E ratio of 20.39. For comparison, its industry has an average Forward P/E of 14.12, which means Johnson & Johnson is trading at a premium to the group.

We can additionally observe that JNJ currently boasts a PEG ratio of 2.32. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.12 at yesterday's closing price.

The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 156, positioning it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research